Charaka Hadinnapola
Overview
Explore the profile of Charaka Hadinnapola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mehmood Z, Assadi H, Li R, Kasmai B, Matthews G, Grafton-Clarke C, et al.
Wellcome Open Res
. 2024 Mar;
8:577.
PMID: 38495400
Aims: Turbulent aortic flow makes the cardiovascular system less effective. It remains unknown if patients with heart failure with preserved ejection fraction (HFpEF) have disturbed aortic flow. This study sought...
2.
Reddy S, Swietlik E, Robertson L, Michael A, Boyle S, Polwarth G, et al.
J Heart Lung Transplant
. 2023 May;
42(9):1275-1285.
PMID: 37201688
Background: We describe baseline characteristics, disease progression and mortality in chronic thromboembolic pulmonary disease patients as a function of mean pulmonary artery pressure (mPAP) according to new and previous definitions...
3.
Machado R, Welch C, Haimel M, Bleda M, Colglazier E, Coulson J, et al.
J Med Genet
. 2021 Sep;
59(9):906-911.
PMID: 34493544
Background: The molecular genetic basis of pulmonary arterial hypertension (PAH) is heterogeneous, with at least 26 genes displaying putative evidence for disease causality. Heterozygous variants in the gene were recently...
4.
Hodgson J, Swietlik E, Salmon R, Hadinnapola C, Nikolic I, Wharton J, et al.
Am J Respir Crit Care Med
. 2019 Oct;
201(5):575-585.
PMID: 31661308
Recently, rare heterozygous mutations in were identified in patients with pulmonary arterial hypertension (PAH). encodes the circulating BMP (bone morphogenetic protein) type 9, which is a ligand for the BMP2...
5.
Sofianopoulou E, Kaptoge S, Graf S, Hadinnapola C, Treacy C, Church C, et al.
Eur Respir J
. 2019 Mar;
53(5).
PMID: 30923185
While traffic and air pollution exposure is associated with increased mortality in numerous diseases, its association with disease severity and outcomes in pulmonary arterial hypertension (PAH) remains unknown.Exposure to particulate...
6.
Newnham M, South K, Bleda M, Auger W, Barbera J, Bogaard H, et al.
Eur Respir J
. 2019 Jan;
53(3).
PMID: 30655285
Chronic thromboembolic pulmonary hypertension (CTEPH) is an important consequence of pulmonary embolism that is associated with abnormalities in haemostasis. We investigated the ADAMTS13-von Willebrand factor (VWF) axis in CTEPH, including...
7.
Rhodes C, Batai K, Bleda M, Haimel M, Southgate L, Germain M, et al.
Lancet Respir Med
. 2018 Dec;
7(3):227-238.
PMID: 30527956
Background: Rare genetic variants cause pulmonary arterial hypertension, but the contribution of common genetic variation to disease risk and natural history is poorly characterised. We tested for genome-wide association for...
8.
Bohnen M, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, et al.
Circ Genom Precis Med
. 2018 Oct;
11(10):e002087.
PMID: 30354297
Background: In pulmonary arterial hypertension (PAH), pathological changes in pulmonary arterioles progressively raise pulmonary artery pressure and increase pulmonary vascular resistance, leading to right heart failure and high mortality rates....
9.
Hadinnapola C, Graf S, Morrell N
Circulation
. 2018 May;
137(22):2413-2414.
PMID: 29844075
No abstract available.
10.
Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al.
Nat Commun
. 2018 Apr;
9(1):1416.
PMID: 29650961
Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious variation within components of the transforming growth factor-β pathway, particularly the bone morphogenetic protein type 2 receptor...